Cary Business: Ockham Acquires Nexus

Story from staff reports. Scanning electron micrograph by Anne Weston for  Wellcome Industries.

Cary, NC – The high-tech focus of Cary business continues to expand with the acquisition of Nexus Oncology by Ockham, a Cary company.

Ockham – Contract Medical Research

Ockham, headquartered at 8000 Regency Parkway, is a Contract Research Organization (CRO). They test new medicines, medical devices, pharmaceutical manufacturing and a host of other clinical applications.

Nexus describes itself as a niche oncology CRO. Ockham’s Chief Executive Officer, James V. Baker, will run the combined company. The organization released this info:

In combining with Nexus, Ockham now employs almost 300 employees across 12 countries, placing it among top-tier niche CROs worldwide.  This merger offers a greater global scale and depth of oncology-specific knowledge.  The new organization is now more strongly positioned in the field of oncologic clinical trials.

First time commenter? Please read our Comments Policy. Comments are at the discretion of the Publisher.